Calibration of a simplified ARIA‐E MRI severity scale suitable for clinical practice
Gregory Klein(Roche (Switzerland)), Geoffrey A. Kerchner(Roche (Switzerland)), Paul Delmar(Roche (Switzerland)), Derk D. Purcell(BioClinica (United States)), Luc Bracoud(BioClinica (United States)), Szofia Bullain(Roche (Switzerland)), Rachelle S. Doody(Baylor College of Medicine), Danielle Abi‐Saab(Roche (Switzerland)), Jerome Barakos(Sutter Health), Paulo Fontoura(Roche (Switzerland)), Monika Baudler(Roche (Switzerland))
Cited by 3
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741